An approach to the use of immunosuppressive drugs in nonmalignant diseases.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006505:Hepatitis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use* / Q000633:toxicity; D008103:Liver Cirrhosis / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008814:Mice, Inbred NZB; D009103:Multiple Sclerosis / Q000188:drug therapy; D009393:Nephritis / Q000188:drug therapy; D009401:Nephrosis / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy; D014606:Uveitis, Anterior / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D009588:Nitrogen Mustard Compounds; D010406:Penicillins; D002699:Chlorambucil; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001241:Aspirin; D008727:Methotrexate